New Weekly Insulin for Pediatric Type 2 Diabetes
The FDA approved a once-weekly insulin injection for children 10 and older to help manage blood glucose alongside diet and exercise.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Would you prefer a once-weekly insulin injection over daily insulin for managing your child's diabetes?
The FDA has expanded the approval of the long-acting insulin analog Awiqli to include pediatric patients aged 10 and older with type 2 diabetes. This medication, which is administered as a once-weekly subcutaneous injection, is intended to be used alongside diet and exercise to help manage blood glucose levels.
Why it matters
Type 2 diabetes involves chronic high blood glucose due to the body’s inability to effectively produce or use insulin. Expanding treatment options for younger patients provides an additional method for managing glucose levels beyond daily injections.
The approval is based on a pharmacometric modeling analysis involving 18 pediatric patients compared against known adult blood level data. This approach projected that the long-acting insulin analog will lower blood glucose in children in a manner similar to its effect in adults.
The players
FDA
The U.S. federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
The details
Awiqli functions as a long-acting insulin analog delivered via a once-weekly subcutaneous injection, designed to supplement a standard regimen of diet and exercise. The drug acts by mimicking the body's natural insulin to regulate blood glucose, with dosing and safety protocols modeled on adult treatment standards to address specific risks like hypoglycemia and accidental overdose.
Timeline
October 23, 2026: The FDA approved Awiqli for pediatric patients aged 10 and older.
Health Landscape
This approval follows the FDA's pediatric drug development priority review process to bring chronic disease therapies to younger age groups. It reflects a shift toward utilizing pharmacometric modeling to expand treatment access for pediatric type 2 diabetes.
Patients and families should discuss the specific risks of hypoglycemia and the importance of precise dosing to avoid accidental overdose with their healthcare provider. It is also essential to continue maintaining the prescribed diet and exercise program alongside this therapy.
The takeaway
When managing type 2 diabetes in children, it is vital to be aware of symptoms of hypoglycemia and to strictly adhere to label warnings regarding medication errors. If considering a transition to long-acting therapies, schedule a conversation with your pediatrician to review the potential benefits and safety requirements.
Further reading
For more on managing long-term blood glucose control, visit our Diabetes section.
Live Poll
Would you prefer a once-weekly insulin injection over daily insulin for managing your child's diabetes?
